IMCR241220P95000
- 0.00
- 0.000.00%
Immunocore Newsroom
Immunocore Hldgs Analyst Ratings
Morgan Stanley Downgrades Immunocore Holdings to Equalweight From Overweight, Cuts Price Target to $35 From $74
Morgan Stanley Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $35
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $74
Immunocore Hldgs Analyst Ratings
Mizuho Securities Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $38
Immunocore Downgraded to Neutral From Outperform at Mizuho
Morgan Stanley Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $74
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
Oppenheimer Trims Immunocore Price Target to $88 From $89, Maintains Outperform Rating
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
Barclays Keeps Their Buy Rating on Immunocore Holdings (IMCR)
Needham Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $71
TD Cowen Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $60
Immunocore Holdings: Strong Market Performance and Promising Pipeline Drive Buy Rating
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
Immunocore Hldgs Analyst Ratings
Morgan Stanley Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $74
Morgan Stanley Lowers Price Target on Immunocore Holdings to $74 From $80, Keeps Overweight Rating
Capital One Financial Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $90